pharma-biotech-2018-posters-abstracts

9 / 25

Page 64
conferenceseries.com
Volume 8 Journal of Biotechnology & Biomaterials
ISSN: 2155-952X Pharma Biotech 2018
December 10-11, 2018
December 10-11, 2018 | Rome, Italy
23rd International Conference on
Pharmaceutical Biotechnology
Formulation and characterization of dacarbazine loaded stearic acid nanoparticle cream and its
cytotoxic potential
Abdul Hafeez and Imran Kazmi
Glocal University, India
In current years, rapid increase in the number of skin cancer patients has led to socio-economic burdenworldwide. Dacarbazine
(DZ) is a single drug approved by US-FDA for the treatment of a type of skin cancer melanoma. DZ have short half-life in
systemic circulation as well as poor water solubility, slow response rate with severe toxicity which limits its market potential.
In view of the above background present study is designed for formulation, characterization and pharmacological evaluation
of dacarbazine laden nanocream (DZC) for the treatment of melanoma. Dacarbazine loaded stearic acid nanoparticles (DZP)
prepared by diffusion method. DZC prepared by oil-in-water emulsion technique by using DZP. Dacarbazine nanoparticle
and its cream were characterized for shape size of particle, drug loading capacity, nanoencapsulation efficacy, zeta potential,
transmission electron microscopy (TEM), pH value, spreadability and viscosity, in vitro drug releasing capacity and its
cytotoxic effect by using MTT assay. The particle size of DZNP and DZNC was 16.3±8.1 nm and 16.9±7.8 nm respectively.
pH value and spreadability of nanoparticle cream were found to be 6.7±0.14 g cm/sec and 55.23±3.13 g cm/sec respectively.
Nanoencapsulation efficiency and drug loading capacity were 67.4±3.5% and 6.73 mg/10 mg respectively. From above results,
it can be concluded that DZC can be effectively utilized for the treatment of melanoma.
J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C8-110